ReNeuron Announces Presentation of Updated Efficacy and Safety Data from Retinitis Pigmentosa Study at the Sixth Annual Retinal Cell and Gene Therapy Innovation Summit

Author's Avatar
Apr 26, 2019
Article's Main Image

hRPC Cell Therapy Demonstrates Sustained and Further Improvement in Vision at 60 and 120 Days in First Cohort of Phase 2a study in Retinitis Pigmentosa

Mean Change from Baseline in Visual Acuity of +23 Letters to Date

PR Newswire